Assessment of residual disease in acute leukemia by means of polymerase chain reaction

Revista de Investigacion Clinica

Volumn 52, Issue 2, 2000, Pages 118-124

  Ruiz Argüelles, Guillermo J ^a,b   Garcés Eisele, Javier ^b   Reyes Núñez, Virginia ^b   Pérez Romano, Beatriz ^b   Ruiz Argüelles, Alejandro ^b   Ramírez Cisneros, Francisco J ^c   López Martínez, Briceida ^d   López Tapia, J Daniel ^d   Rivadeneyra Espinoza, Liliana ^b  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c UNIVERSIDAD POPULAR AUTÓNOMA DEL ESTADO DE PUEBLA   (Mexico)

^d BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

Acute; Leukemia; Molecular; PCR; Residual disease

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; ONCOPROTEIN; TUMOR MARKER;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STEM CELL; CHEMISTRY; CHILD; FEMALE; GENETICS; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LIFE TABLE; MALE; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DNA, COMPLEMENTARY; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA; LIFE TABLES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS;

EID: 0034152301     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Romero F, Paredes R. Definición de riesgos en leucemia aguda, de acuerdo a la clasificación. In: Ruiz-Argüelles GJ, San-Miguel JF (editors). Actualización en leucemias. Mexico City, Mexico: Editorial Médica Panamericana. 1996; 41-9.
2. Salamanca F, Garcés-Eisele J. Utilidad de la citogenética y biología molecular en el estudio de las leucemias agudas. In: Ruiz-Argüelles GJ, San-Miguel JF (editors). Actualización en leucemias. México City, México: Editorial Médica Panamericana, 1996; 35-40.
3. Pui CH. Childhood leukemias. N Engl J Med 1995; 332: 1618-22.
4. Hagenbeck A, Martens AM. Minimal residual disease in acute leukemia: Preclinical studies in a relevant rat model. Baillieres Clin Haematol 1991; 4: 609-15.
5. San-Miguel JF, Ortao A, Ruiz-Argüelles A. Identificación y vigilancia de enfermedad residual minima en leucemia aguda. In: Ruiz-Argüelles GJ, San-Miguel JF (editors). Actualización en leucemias. Mexico City, Mexico: Editorial Médica Panamericana, 1996; 65-9.
6. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 1995; 85: 1416-20.
7. Pui CH, Campana D. Detection of minimal residual disease in acute leukaemia. In: Mc Arthur JR, Lee SH, Wong JEL, Ong YW (editors). Haematology. Education Programme of the 26th Congress of the International Society of Haematology 1996; 137-42.
8. San-Miguel JF, Orfao A, Pongers-Willemse MJ, van Dongen JM. Detection of minimal residual disease in acute leukemia. In: Willemse R, Mc Arthur JR, Degos L (editors). Haematology. Education Program of the 27th Congress of the International Society of Hematology. 1998; 22-9.
9. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CHH, Abromovitch M et al. Improved outcome in acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-6.
10. Ruiz-Argüelles GJ, Apreza-Molina MG. Resultados del tratamiento de las leucemias agudas en adolescentes. Rev Invest Clin Méx 1997; 49:271-5.
11. Ruiz-Argüelles GJ, Apreza-Molina MG, Alemán-Hoey DD, Gómez-Almaguer D, Marín-López A, Mercado-Díaz L. Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: A multicentre study. Eur J Haematol 1995; 54: 18-20.
12. Ruiz-Argüelles GJ, Garcés-Eisele J, Ruiz-Argüelles A. Molecular follow-up of patients with promyelocytic leukaemia treated with all trans-retinoic acid. Clin Lab Haematol 1998, 20: 173-6.
13. Ruiz-Argüelles A, Duque E, Orfao A. Report on the first Latinamerican consensus conference for flow cytometric immunophenotyping of leukemia. Cytometry (Comm Clin Cytometry) 1998; 34: 39-42.
14. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analytical Biochem 1987; 162: 156-9.
15. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. 2nd Ed. Cold Spring Harbor Laboratory Press, New York, 1989.
16. Deane M, Norton JD. Immunoglobulin gene fingerprinting. An approach to analysis of B lymphoid clonality in lymphoproliferative disorders. Brit J Haematol 1991; 77: 274-81.
17. Height SE, Swansbury GJ, Matutes E, Treleaven E, Catovsky D, Dyer MJS. Analysis of clonal rearrangements of the Ig heavy chain locus in acute leukemia. Blood 1996, 12: 5242-50.
18. Reyes-Núñez V, Ruiz-Argüelles A, Ruiz-Argüelles GJ, Garcés-Eisele J. Improved molecular detection of minimal residual disease in lymphoid neoplasms. Abstracts of the International Symposium on Minimal Residual Disease, Salamanca Spain. 1997; 88.
19. Reyes-Núñez V. Molecular detection of minimal residual disease in patients with acute lymphoblastic leukemia. Masters Degree Thesis. Chemistry School. Universidad de las Américas, Puebla, México. February 1998.
20. Biondi A, Rambaldi A, Pandolfi PP, Rossi V, Giudici G, Alcalay et al. Molecular monitoring of the myl/retinoic acid receptor-a fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992, 80: 492-7.
21. Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H et al. Junctions of the AML1/MTG8 (ETO) fusion are constant in t (8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993; 82: 1270-6.
22. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AMLI fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997; 90: 4933-7.
23. Claxton DF, Liu P, Hsu HB, Marlton P, Hester J, Collins F et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 1994, 83: 1750-6.
24. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín-López A, Delgado-Lamas JL. Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed entirely on an outpatient basis. Am J Hematol 1998,58: 161-4.
25. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín-López A, Larregina-Díez A, Apreza-Molina MG. Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy. Am J Hematol 1995; 48: 100-3.
26. Ruiz-Argüelles GJ. Promyelocytic leukemia in Mexican Mestizos. Blood 1997; 89: 348-9.
27. Garcés-Eisele J, Ruiz-Argüelles GJ, Marín-López A. Investigación de la fusión molecular PML/RARα en leucemia aguda promielocítica (LAM-M3) por medio de la reacción en cadena de la polimerasa con transcriptasa inversa (RT-PCR). Sangre 1995; 40: 246.
28. Rubnitz JE, Downing JR, Pui CH et al. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance. J Clin Oncol 1997; 15: 1150-8.
29. Larson RA, Stock W, Hoelzer DF, Kantarjian H. Acute lymphoblastic leukemia in adults. In: Mc Arthur JR, Schechter GP, Schrier SL. Hematology. Washington, U.S.A.: The American Society of Hematology Education Program Book. 1998; 44-62.
30. Seale J, Varma S, Swirsky D, Goldman J, Cross N. Quantification of the PML/RARα fusion mRNA in acute promyelocytic leukemia: Quality control of procedures used for the detection of minimal residual disease. Britt J Haematol 1997; (Suppl. 1): 51.